Abstract Details

Title Evaluation of Sleep Disorders and Polisomnographic Findings in Behcet and Neurobehcet Disease

Topic Neurotoxicology

Presentation(s) P06 - (-)

Poster/Presentation
Number 219

Objective

Background BACKGROUND: Involvement of the central nervous system (CNS) in Behcet's disease is one of the most devastating presentation of Behcet's disease (BD). Neuro-Behcet disease (NBD) was divided into two main categories, as parenchymal and non-parenchymal involvement. The most common site of involvement being the brainstem. On the other hand, the critical importance of this anatomical region in the regulation of sleep has been disregarded in the literature. In this study, we aimed

Design/Methods DESIGN/METHODS: Patients were grouped into two as (i) patients with BD without any neurological involvement, and (ii) patients with NBD having brainstem lesions. A control group consisting age- and gender-matched healthy subjects was also enrolled into this study. Polisomnographic (PSG) records was applied to all patients, subjective sleep quality was evaluated by Pittsburgh Sleep Quality Test (PSQT), and daytime excessive sleepiness was tested by Epworth Sleepiness Scale (ESS).

Results RESULTS: None of the PSG parameters displayed significant differences between with BD, NBD and control group. On the other hand, the comparison of PSG parameters between all patients (BD and NBD) with the control group did show that sleep onset was significantly longer (p=0.006), the duration of superficial NREM sleep stage (N2) was significantly longer (p=0.018), and RDI was significantly higher (p=0.034) in patients. RLS was significantly more common in patients with BD and NBD in compared to healthy subjects (p=0.040).

Conclusions CONCLUSIONS: Although there was no clinical and polisomnographic discrepancy among BD and NBD, we exhibited worsening of sleep macroorganization and increased sleep disturbances in all BD group with respect to control group. Consequently in Behcet patients seeking somatic symptoms that was not attributable to BD, obstructive sleep apnea syndrome and restless legs syndrome must be keep in mind.

Authors/Disclosures
PRESENTER	No disclosure on file
Ugur Uygunoglu (Cerrahpasa)	Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine)	Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.

��ɫ��

��ɫ��